Navigation Links
Covance Establishes New Discovery & Translational Services Group
Date:5/10/2010

 

PRINCETON, N.J., May 10 /PRNewswire-FirstCall/ -- Covance Inc. (NYSE: CVD), a leading provider of drug R&D services, announced today that it has created a new Discovery & Translational Services group, which will integrate its discovery services, antibody products and immunology services, Biomarker Center of Excellence, and Genomics Laboratory. Leveraging its minority equity stake in Caprion Proteomics, Inc. and alliance with Rules-Based Medicine, Inc., Covance's Discovery & Translational Services group will offer clients a depth and breadth of drug discovery and biomarker services that is unmatched in the CRO industry.

"Increasingly our clients are looking for drug development companies that can provide a full spectrum of services and expertise from early drug discovery through late-stage clinical trials and post-marketing surveillance," said Joe Herring, Chairman and Chief Executive Officer of Covance Inc. "Through a series of strategic investments and alliances, we have enhanced our early-stage drug R&D capabilities and gained an impressive array of world-class talent and technologies in genomics, proteomics, biomarkers, and discovery services such as early safety and efficacy testing, in vivo pharmacology and imaging. As a result, Covance now has a comprehensive range of integrated services across the drug R&D continuum that can help clients make faster and more effective decisions about their portfolios."

Discovery & Translational Services will report to Deborah Tanner, Corporate Senior Vice President at Covance; President, Central Laboratory Services and President, Discovery & Translational Services. Said Ms. Tanner, "By uniting our discovery and translational services under one operating umbrella we can better leverage current capabilities, foster greater scientific and technical collaboration, and ultimately provide greater value to our clients through a portfolio of services that parallel their drug development model."

Jonathan Koch has been appointed Vice President and General Manager, Discovery & Translational Services.  Mr. Koch most recently held the position of Vice President and General Manager for the Covance Greenfield, Indiana campus.

With its Discovery and Translational Services group Covance is uniquely positioned to provide clients with an integrated set of discovery capabilities and leverage a range of translational tools such as imaging, biomarkers and genomics across its broad portfolio of development services.  "Our goal is to generate data that yields more effective results for clients," said Dr. Tom Turi, Vice President, Science and Technology for Discovery and Translational Services.  "Through our enhanced discovery services we are able to provide clients with decision-driving information earlier in, and throughout, the drug development process."

About Covance

Covance, with headquarters in Princeton, New Jersey, is one of the world's largest and most comprehensive drug development services companies with annual revenues greater than $1.8 billion, global operations in more than 30 countries, and more than 10,000 employees worldwide. Information on Covance's products and services, recent press releases, and SEC filings can be obtained through its website at www.covance.com.

Statements contained in this press release, which are not historical facts, are forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All such forward-looking statements including the statements contained herein regarding anticipated trends in the Company's business are based largely on management's expectations and are subject to and qualified by risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, without limitation, competitive factors, outsourcing trends in the pharmaceutical industry, levels of industry research and development spending, the Company's ability to continue to attract and retain qualified personnel, the fixed price nature of contracts or the loss of large contracts, and other factors described in the Company's filings with the Securities and Exchange Commission.


'/>"/>
SOURCE Covance Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology news :

1. Academy establishes Asia Center to protect the environment
2. Sharper image: UH optometrist establishes sports vision clinic
3. Rice University establishes National Corrosion Center
4. UBC study establishes formula for predicting climate change impact on salmon stocks
5. The last supper of the hominids establishes the times they lived at the sites
6. $29.4 million grant establishes CTSI at NYU in partnership with Health and Hospitals Corporation
7. MU research team establishes family tree for cattle, other ruminants
8. March of Dimes establishes 2 new perinatal bioethics awards
9. TGen Drug Development establishes European footprint
10. DFG establishes 10 new research units
11. Innovalight Establishes New Record With Silicon Ink Solar Cells
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/26/2016)... BANGALORE, India and LONDON ... Infosys Finacle, part of EdgeVerve Systems, a ... ), and Onegini today announced a partnership to ... banking solutions.      (Logo: http://photos.prnewswire.com/prnh/20151104/283829LOGO ... banks to provide their customers enhanced security to ...
(Date:4/19/2016)... April 20, 2016 The new ... a compact web-based "all-in-one" system solution for all door ... reader or the door interface with integration authorization management ... control systems. The minimal dimensions of the access control ... the building installations offer considerable freedom of design with ...
(Date:4/15/2016)... 15, 2016 Research and ... Biometrics Market 2016-2020,"  report to their offering.  , ... , ,The global gait biometrics market is expected ... the period 2016-2020. Gait analysis generates ... be used to compute factors that are not ...
Breaking Biology News(10 mins):
(Date:6/23/2016)...   EpiBiome , a precision microbiome engineering company, ... financing from Silicon Valley Bank (SVB). The financing will ... its drug development efforts, as well as purchase additional ... has been an incredible strategic partner to us – ... would provide," said Dr. Aeron Tynes Hammack , ...
(Date:6/23/2016)... ... , ... STACS DNA Inc., the sample tracking software company, today announced that ... joined STACS DNA as a Field Application Specialist. , “I am thrilled that ... of STACS DNA. “In further expanding our capacity as a scientific integrator, Hays brings ...
(Date:6/23/2016)... Ky. , June 23, 2016 ... two Phase 1 clinical trials of its complement ... placebo-controlled, single and multiple ascending dose studies designed ... pharmacodynamics (PD) of subcutaneous injection in healthy adult ... subcutaneously (SC) either as a single dose (ranging ...
(Date:6/23/2016)... June 23, 2016 ... 2016;12(1):22-8 http://doi.org/10.17925/OHR.2016.12.01.22 Published recently ... peer-reviewed journal from touchONCOLOGY, Andrew D Zelenetz ... of cancer care is placing an increasing burden ... expensive biologic therapies. With the patents on many ...
Breaking Biology Technology: